Abstract
Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.
Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.
Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.
Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
Keywords: Acute coronary syndrome, clinical efficacy, clopidogrel besylate, coronary artery disease, generic clopidogrel, peripheral artery disease, stroke.
Current Vascular Pharmacology
Title:Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Volume: 13 Issue: 6
Author(s): Kyriafina Terzoudi, Spiros Konstantinou, Haralampos Milionis, Adamantios Bourdakis, Dimitrios Nikolopoulos, Leonidas Peltekis, Nikos Prokopakis, Ioannis Sinteles, Christos S. Stroumbis, Nikolaos Kipouridis, Karmelos Tsilias, Ioannis Xaraktsis, Christos Charmpas, Georgios Hatziathanasiou, Zacharias Christogiannis, Demosthenes B. Panagiotakos, John A. Goudevenos, Alexandros D. Tselepis, Ioannis Giatrakos, Kalliroi I. Kalantzi, Maria E. Tsoumani, John N. Vakalis, Vasileios Vasilakopoulos, Konstantinos Vardakis, Konstantinos N. Vemmos, Maria Voukelatou, Georgios Giannakoulas, Ioannis V. Ntalas, Vasileios Giogiakas, Georgios Goumas, Nikos Dimoulis, Antonios Draganigos, Ioannis Efthimiadis, Maria Thoma and Evangelos Kazakos
Affiliation:
Keywords: Acute coronary syndrome, clinical efficacy, clopidogrel besylate, coronary artery disease, generic clopidogrel, peripheral artery disease, stroke.
Abstract: Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.
Methods: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.
Results: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.
Conclusion: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).
Export Options
About this article
Cite this article as:
Terzoudi Kyriafina, Konstantinou Spiros, Milionis Haralampos, Bourdakis Adamantios, Nikolopoulos Dimitrios, Peltekis Leonidas, Prokopakis Nikos, Sinteles Ioannis, Stroumbis S. Christos, Kipouridis Nikolaos, Tsilias Karmelos, Xaraktsis Ioannis, Charmpas Christos, Hatziathanasiou Georgios, Christogiannis Zacharias, Panagiotakos B. Demosthenes, Goudevenos A. John, Tselepis D. Alexandros, Giatrakos Ioannis, Kalantzi I. Kalliroi, Tsoumani E. Maria, Vakalis N. John, Vasilakopoulos Vasileios, Vardakis Konstantinos, Vemmos N. Konstantinos, Voukelatou Maria, Giannakoulas Georgios, Ntalas V. Ioannis, Giogiakas Vasileios, Goumas Georgios, Dimoulis Nikos, Draganigos Antonios, Efthimiadis Ioannis, Thoma Maria and Kazakos Evangelos, Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150316220515
DOI https://dx.doi.org/10.2174/1570161113666150316220515 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Crocetin Attenuates Spatial Learning Dysfunction and Hippocampal Injury in a Model of Vascular Dementia
Current Neurovascular Research Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease
Current Pharmaceutical Design Leptin and Inflammation
Current Immunology Reviews (Discontinued) Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Editorial: Effective Bio-EconomicApproaches for StemCell Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Pharmacogenomic Considerations of the Insertion / Deletion Gene Polymorphism of the Angiotensin I-Converting Enzyme and Coronary Artery Disease
Current Vascular Pharmacology The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry The Effect of Borage (Echium amoenum) on the Mouse Heart and Hematology Parameters
Cardiovascular & Hematological Disorders-Drug Targets Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews The Association of Very High Hair Manganese Accumulation and High Oxidative Stress in Mongolian People
Current Aging Science Metabolomics Reveals Hyperlipidemic Biomarkers and Antihyperlipidemic Effect of Poria cocos
Current Metabolomics Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
Current Pharmaceutical Design Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Structure-to-function Relationship of Carbohydrates in the Mechanism of Lysosomal Storage Disorders (LSDs)
Current Organic Chemistry